BMJ Open

Updated systematic review of Australian school-based prevention programmes for alcohol and other drugs: a review protocol

Emma Krogh Devine, Maree Teesson, Jennifer Debenham, Tara Guckel, Lexine Ann Stapinski, Emma Barrett, Katrina Elizabeth Champion, Cath Chapman, Nicola Clare Newton

ABSTRACT

Introduction Adolescent onset substance use is associated with neurodevelopmental, social and psychological harms. Thus, alcohol and other drug prevention programmes are essential to promote health and well-being during this period. Schools are uniquely positioned to deliver such prevention programmes. The last decade has seen a large expansion of school-based alcohol and drug prevention programmes in Australia, warranting an update of the comprehensive review conducted by Teesson et al in 2012. This proposed review aims to (1) identify school-based substance use prevention programmes that have been trialled in Australia since 2011, (2) evaluate their efficacy and (3) identify intervention components associated with effectiveness. This will assist schools in identifying and adopting effective evidence-based programmes and inform future programme development, evaluation and policy.

Methods and analysis Studies published from 2011 will be identified by searching the electronic databases PubMed, PsycINFO, Medline, Embase, ProQuest and Cochrane Library in addition to grey literature searches. Eligible studies will be controlled trials (including randomised controlled trials, cluster randomised controlled trials and quasi-experimental trials) of programmes measuring drug and alcohol related outcomes that are conducted in a school setting and have been trialled within Australia. Records will be independently screened for eligibility by two review authors, with disagreements being resolved by consensus or a third review author where necessary. Data extraction, risk of bias and study quality will also be completed independently by two review authors. A qualitative synthesis of all eligible studies will be presented. In addition, if there are sufficient data to combine studies, a random-effects meta-analysis will be conducted.

Ethics and dissemination This research is exempt from ethics approval as no primary data are collected, with work instead being carried out on published documents. The findings of this proposed review will be disseminated in a peer-reviewed journal and at conferences.

STRENGTHS AND LIMITATIONS OF THIS STUDY

⇒ This review will provide an important update on the existing alcohol and other drug prevention programmes for adolescents in Australia, with the aim of enabling schools to adopt effective evidence-based prevention programmes and informing future programme development, evaluation and policy.
⇒ Screening, data extraction, risk of bias and quality assessments will be performed independently by two study authors with experience in systematic review methodologies.
⇒ The proposed review will be written in line with the Preferred Reporting Items for Systematic Review and Meta-Analysis statement and use validated measures to assess quality and risk of bias.
⇒ The heterogeneity of the interventions, the outcomes and the tools used to measure the outcomes may not allow for direct comparisons between studies or pooling of results.

PROSPERO registration number CRD42021272959.

INTRODUCTION

Adolescence marks the onset and escalation of substance use. Although early adolescents (12–14 years) are driving global downward trends in substance use,1–3 middle and late adolescents (15–19 years) continue to consume substances in risky quantities.4,5 In Australia, first-time alcohol use tends to occur between 15 and 17 years.6–8 Findings from the Australian National Drug Strategy Household Survey report the average age of alcohol initiation to be 16.2 years, with binge drinking being the most common form of alcohol consumption in this age group.9 One quarter (26%) of 16–17-year-olds engage in binge drinking (consuming five or more standard drinks per day10) in the past fortnight.11 In line with alcohol use, the average age of first-time cigarette smoking is 16.6...
years (median age is 17 years\textsuperscript{13}), with 7% of 16–17 years
reporting monthly cigarette use.\textsuperscript{8,9} In Australia, the
average age of first-time cannabis use is 18.9 years,\textsuperscript{9} while
those who use other illicit substances tend to first try
them in their 20s.\textsuperscript{9,13} Among 16–17-years, 16%, 5% and
2% report past monthly cannabis, ecstasy and cocaine
use, respectively.\textsuperscript{9,11} Onset of substance use during
adolescence is linked to cumulative and pervasive harms
spanning neurodevelopmental, social, and psychological
domains,\textsuperscript{14,15} and increases the chances of future
dependence and co-occurring mental health disorders.\textsuperscript{16}
Adolescents are the foundation of future population
health, and evidence-based prevention is essential to
promote health during this period.

Schools are uniquely positioned to deliver prevention
programmes to a large number of young people and
implementation costs are generally low.\textsuperscript{17} Australia’s
mandatory drug and alcohol health curricula grants all
students access to universal prevention (delivered to all
students regardless of their level of risk for substance
use) throughout most of their schooling. However,
currently many schools do not implement evidence-
based prevention programmes.\textsuperscript{18,19} Of those evidence-
based programmes currently delivered, the strength
and sustainability of effects vary substantially, and most
programmes confer small to moderate effects, which tend
to diminish in the senior years of school.\textsuperscript{19} Commonly,
effective programmes adopt some but not all evidence-
based principles and the impact of implementation factors
(e.g., fidelity, engagement, dosage) are not adequately
explored.\textsuperscript{30} The changing trends in adolescent substance
use and the evolving social and technological environ-
ment must be met with equivalent progress in prevention
programme development, adaptation and implementa-
tion to ensure students have access to the most effective
programmes before the transition into adulthood.

When evaluating alcohol and other drug prevention
programmes for use in Australian schools, it is important
to consider those that have been trialled in Australia as
policies, regulations, behaviours and attitudes can differ
between countries.\textsuperscript{21–23} This is especially relevant for
school-based prevention programmes because school
systems and school drug policies differ between coun-
tries.\textsuperscript{21,24} For example, Australia is unique in having drug
and alcohol education forming a mandatory part of the
school curriculum and Australian school drug policy
setting processes are more likely to take a whole school
community approach compared with other countries such
as the USA.\textsuperscript{25} Moreover, research suggests that patterns of
adolescent substance use are changing in Australia and
that young people begin using alcohol and other drugs at
an older age compared with adolescents in other Western
countries.\textsuperscript{26–28} Age of substance use initiation will impact
the time at which school-based prevention programmes
are implemented and consequently the content within
the programme to ensure it is age appropriate. As such,
it is important to consider those that are appropriate for
the Australian context.

Teesson et al\textsuperscript{29} conducted a comprehensive system-
atic review of existing Australian school-based prevention
programmes and identified a small number that
were found to be effective. Since then, there has been
a large expansion of available programmes in Australia,
warranting an update of this review. Moreover, Teesson et al’s\textsuperscript{29} review focused on universal prevention (delivered
to the entire year group regardless of risk for alcohol and
drug use) and could be expanded to include the growing
number of selective prevention programmes (delivered to
students at risk of substance use) demonstrating successful
prevention effects in schools.\textsuperscript{30} Similarly, although digital
school-based prevention programmes were captured in
Champion et al’s 2013 review,\textsuperscript{31} this requires an update in
the Australian environment. Other reviews and meta-
analyses conducted more recently, do not focus on the
unique Australian context,\textsuperscript{20} tend to include studies from
2013 or earlier,\textsuperscript{20} exclusively focus on alcohol\textsuperscript{32–34} or
drug use outcomes\textsuperscript{35} or include universal programmes
only.\textsuperscript{9,36,37} To our knowledge, there has been no system-
atic synthesis of school-based alcohol and drug prevention
programmes, conducted in Australia in the past decade.

To address these gaps in the literature, to enable
schools to adopt effective evidence-based prevention
programmes and to inform future programme develop-
ment, evaluation and policy, a systematic review of all
universal and selective alcohol and other drug preven-
tion programmes trialled in Australian schools since 2011
will be conducted. Specifically, the main objectives of the
planned review are to:

1. Determine the existence of school-based alcohol and
other drug prevention programmes that have been tri-
alled in Australia.
2. Evaluate the efficacy of the school-based programmes
for alcohol and other drug prevention that have been trialled in Australia.
3. Identify the components of Australian school-based
prevention programmes associated with effectiveness,
including both programme content and implementa-
tion factors.

METHODS AND ANALYSIS

This protocol was written in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocol (PRISMA-P) guidelines\textsuperscript{38} (see online supple-
mental file 1). In addition, the planned systematic review
has been registered with the International Prospective
Register of Systematic Reviews (PROSPERO; registration
number: CRD42021272959) and will be written in accor-
dance with the PRISMA statement.\textsuperscript{39}

Eligibility criteria

Eligible studies will be prevention programmes that
include knowledge or use of alcohol and/or drugs as
an outcome variable, regardless of the extent to which
the programme explicitly addresses substance use. Both
universal and selective prevention approaches will be
included in this planned review. Studies must be controlled trials, including randomised controlled trials, cluster randomised controlled trials, or quasi-experimental trials. The prevention programme must also be conducted in a school setting, however, school-based interventions that incorporate additional components (eg, family components) will also be included in the review. Finally, the intervention programme must either be developed in Australia, or be an overseas programme that has been trialled in Australia, to be eligible for inclusion.

**Search strategy**
A search will be conducted using the following databases: PubMed, PsycINFO, Medline, Embase, ProQuest and Cochrane Library. The search terms will be based on those of Teesson et al. and will include terms relating to school or student, alcohol and other drug use, prevention or intervention, and Australia. An example search strategy for Medline can be found in online supplemental file 2. To provide an update on the 2012 systematic review by Teesson et al., the search will be limited to research published in English from July 2011 onwards. Grey literature (eg, dissertations/theses, conference papers) will also be included in this review, and a grey literature search will be conducted to identify any additional relevant studies. This will involve searching clinical trial registries and health related websites, such as those listed in the Grey Matters Tool.

All results identified using this search strategy will be imported into the Covidence online software program for deduplication and screening. The reference lists of eligible studies will be reviewed, using forward (examining the studies cited in the eligible study) and backward (examining the studies that cite the eligible study) searching methods and recent related systematic reviews will also be consulted to identify any additional relevant studies. Also, the authors of eligible studies will be contacted and invited to provide any additional published or unpublished outcome data to be included in the review.

**Screening and data extraction**
Two review authors will independently screen all titles and abstracts identified using the above search strategy against the eligibility criteria. Next, the full texts of potentially eligible studies identified from the title and abstract screening will be independently assessed for eligibility by two review authors. Any disagreement between reviewers regarding the eligibility of studies, both at the title and abstract and full-text screening stage, will be resolved by consensus, or by discussion with a third review author when needed.

Data will be extracted independently by two review authors using a standardised prepiloted form. Extracted data will include publication details (eg, study author, year of publication); study characteristics (eg, study design); participant characteristics (eg, sample size, age, gender, ethnicity, geographical location, socioeconomic status, attrition rates, details of the comparison/control group); intervention characteristics (eg, prevention approach that is, universal or selective, drug(s) targeted, content and theoretical basis); implementation characteristics (eg, frequency of delivery, delivery method); and outcomes of interest (eg, how they were measured, result estimates). Where outcome data are presented in figures, and not also within the text of eligible studies, we will use the WebPlotDigitizer software to extract the data. In addition, where required, the corresponding author of included studies will be contacted by email to obtain any required information or data not included in the published paper. Any discrepancies between the data extracted by the two review authors will be resolved by consensus, with a third reviewer being consulted where necessary.

**Outcomes**
The primary outcomes of interest for the planned review relate to alcohol and other drug use and will include (1) alcohol-related and/or other drug-related knowledge, (2) use of alcohol and/or other drugs and (3) frequency of alcohol and/or other drug use at baseline and post-test and/or follow-up. Trials will be considered effective if statistically significant differences are reported between the intervention and the comparison groups (including active control groups) on any of these outcomes over time. Secondary outcomes of the prevention programmes will also be examined, where present, in this proposed review. These may include alcohol and other drug-related outcomes (eg, attitudes towards alcohol and other drugs, intentions to use, refusal skills, normative perceptions, risk perceptions), behavioural outcomes (eg, self-control, motivation, aggression, assertiveness), school-based outcomes (eg, academic achievement, class climate) and other psychological outcomes (eg, self-esteem, self-awareness) including mental health outcomes (eg, symptoms of anxiety, depression).

**Risk of bias and quality assessment**
The risk of bias of included studies in the planned review will be assessed using the revised Cochrane risk of bias tool for randomised trials (RoB 2.0). This tool assesses potential bias across the following five domains: the randomisation process; deviations from the intended intervention; missing outcome data; measurement of the outcome; and the selection of the reported results. Scores will be summed across the five domains to produce an overall risk of bias score for each study. Two review authors will independently assess the risk of bias of the included studies, with any discrepancies between the two raters being resolved by discussion, with a third review author being consulted where required. In addition, the planned review will use the Grading Recommendations, Assessment, Development and Evaluation framework to assess the quality of included studies.

**Analysis**
In the planned review, we will conduct a qualitative synthesis on the following study aspects: study design
Once completed, the findings from this proposed review will be submitted to a peer-reviewed journal and be disseminated at relevant conferences.

**DISCUSSION**

Given the concerning trends of alcohol and other drug use in adolescents, along with the resulting serious and pervasive negative outcomes associated with substance use, it is critical that Australian youth are receiving evidence-based and effective prevention programmes. A systematic review is an appropriate approach for synthesising the school-based prevention programmes currently available or trialled in Australia, thereby making the evidence more accessible to schools and policy makers. Many of the existing reviews of school-based prevention programmes for alcohol and other drug use do not focus on the Australian context, limit their scope to either alcohol or drug use outcomes, focus on universal prevention approaches only, or require an update given the expansion of prevention programmes over the last decade. Thus, this review will address the existing gaps in the literature and serve to identify which programmes are effective at preventing alcohol and other drug use among school-based youth in Australia, in addition to informing policy and the development of future prevention programmes.

**Patient and public involvement**

There was no patient or public involvement in the conception of this systematic review protocol.

**Ethics and dissemination**

A systematic review is a secondary analysis of the available literature and, as such, ethical approval is not required.
REFERENCES

1. Kraus L, Seitz N-N, Piонтек D, et al. ‘Are the times A-Changin’? trends in adolescent substance use in Europe. Addiction 2018;113:1317–32.
2. Kerr WC, Greenfield TK, Ye Y, et al. Are the 1976–1985 birth cohorts heavier drinkers? age-period-cohort analyses of the National alcohol surveys 1979-2010. Addiction 2013;108:1038–48.
3. Meng Y, Holin J, Hill-McManus D, et al. Trend analysis and modelling of gender-specific age, period and birth cohort effects on alcohol abstention and consumption level for drinkers in Great Britain using the general lifestyle survey 1984-2009. Addiction 2014;109:206–15.
4. Callinan S, Penny A, Livingston M, et al. Patterns of alcohol consumption in 16 cohorts of Australian young adults aged 15–24 between 2001 and 2016. Addiction 2020;115:1452–8.
5. Abo S. Apparent consumption of alcohol. Canberra: Australia, 2013.
6. Smout A, Newton NC, Slade T, et al. The relationship between early risk-taking behavior and mental health problems among a nationally representative sample of Australian youth. J Affect Disord 2020;272:239–48.
7. Aiken A, Clare PJ, Wadolowski M, et al. Age of alcohol initiation and progression to binge drinking in adolescence: a prospective cohort study. Alcohol Clin Exp Res 2018;42:100–10.
8. Livingston M, Holmes J, Oldham M, et al. Trends in the sequence of first alcohol, cannabis and cigarette use in Australia, 2001-2016. Drug Alcohol Depend 2020;207:107821.

9. AIHW. National drug strategy household survey 2019. Canberra: AIHW, 2020.
10. Health AGN, Council MR. Australian guidelines to reduce health risks from drinking alcohol. Canberra: Commonwealth of Australia, 2020.
11. Guenn N, White V. ASSAD 2017 statistics & trends: Australian secondary students’ use of tobacco, alcohol, over-the-counter drugs, and illicit substances. Cancer Council Victoria 2018.
12. Weber MF, Sarich PEA, Vanecova P, et al. Cancer incidence and cancer death in relation to tobacco smoking in a population-based Australian cohort study. Int J Cancer 2021;149:1076–88.
13. Ju H, Jones M, Mishra GD. Illicit drug use, early age at first use and risk of premenstrual syndrome: a longitudinal study. Drug Alcohol Depend 2015;152:209–17.
14. Lees B, Debenham J, Szquegila LM. Alcohol and cannabis use and the developing brain. Alcohol Res 2021;41:11.
15. Degertunel CI, Charon NF, Ferrà S, et al. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet Psychiatry 2018;5:987–1012.
16. Hall WD, Patton G, Stockings E, et al. Why young people’s substance use matters for global health. Lancet Psychiatry 2016;3:265–79.
17. Tancred T, Paparini S, Melendez-Torres GJ, et al. A systematic review and synthesis of theories of change of school-based interventions integrating health and academic education as a novel means of preventing violence and substance use among students. Syst Rev 2018;7:1–22.
18. Das JK, Salam RA, Arshad A, et al. Interventions for adolescent substance abuse: an overview of systematic reviews. J Adolesc Health 2016;59:561–75.
19. Tremblay M, Baydalal L, Khan M, et al. Primary substance use prevention programs for children and youth: a systematic review. Pediatrics 2020;146.
20. Onrust SA, Otten R, Lammers J, et al. School-Based programmes to reduce and prevent substance use in different age groups: what works for whom? systematic review and meta-regression analysis. Clin Psycho Rev 2016;44:45–59.
21. Coligens P, de Graaf I, Bohlmeijer E. Adapting and disseminating effective public health interventions in another country: towards a systematic approach. Eur J Public Health 2005;15:166–9.
22. Ashton T. Implementing integrated models of care: the importance of the macro-level context. Int J Integr Care 2015;15:e019.
23. Barrera M, Castro FG, Stryker LA, et al. Cultural adaptations of behavioral health interventions: a progress report. J Consult Clin Psychol 2013;81:196–205.
24. Evans-Whipp T, Beyers JM, Lloyd S, et al. A review of school drug policies and their impact on youth substance use. Health Promot Int 2004;19:227–34.
25. Beyers JM, Evans-Whipp T, Mathers M, et al. A cross-national comparison of school drug policies in Washington state, United States, and Victoria, Australia. J Sch Health 2005;75:134–40.
26. Bräker AB, Soellner R. Alcohol drinking cultures of European adolescents. Eur J Public Health 2016;26:581–6.
27. Kraus L, Nicolar A. ESPAD report 2015: results from the European school survey project on alcohol and other drugs: European monitoring centre for drugs and drug addiction 2016.
28. Moor I, Winter K, Rathmann K, et al. Alcohol, tobacco and cannabis use in adolescence - Cross-sectional results of the 2017/18 HBS study. J Health Monit 2020;5:69.
29. Teesson M, Newton NC, Barrett EL. Australian school-based prevention programs for alcohol and other drugs: a systematic review. Drug Alcohol Rev 2012;31:731–6.
30. Newton NC, Stapinski LA, Slade T, et al. The 7-year effectiveness of school-based alcohol use prevention from adolescence to early adulthood: a randomized controlled trial of universal, selective, and combined interventions. J Am Acad Child Adolesc Psychiatry 2022;61:19:520–32.
31. Champion KE, Newton NC, Barrett EL, et al. A systematic review of school-based alcohol and other drug prevention programs facilitated by computers or the Internet. Drug Alcohol Rev 2013;32:115–23.
32. Foxcroft DR, Ts tertsvadze A. Universal alcohol misuse prevention programmes for children and adolescents; cochrane systematic reviews. Perspect Public Health 2012;132:128–34.
33. Lee NK, Cameron J, Battams S, et al. What works in school-based alcohol education: a systematic review. Health Educ J 2016;75:780–98.
34. Hennessy EA, Tanner-Smith EE. Effectiveness of brief school-based interventions for adolescents: a meta-analysis of alcohol prevention programs. Prev Sci 2015;16:463–74.
35. Faggiano F, Minozzi S, Versino E. Universal school-based prevention for illicit drug use. Cochrane Database Syst Rev 2014;12.
36. Agabio R, Trincas G, Floris F, et al. A systematic review of school-based alcohol and other drug prevention programs. Clin Pract Epidemol Ment Health 2015;11:102–12.
37. Mewton L, Visontay R, Chapman C, et al. Universal prevention of alcohol and drug use: an overview of reviews in an Australian context. Drug Alcohol Rev 2018;37 Suppl 1:S435–69.
38. Moher D, Shamseer L, Moher M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1–9.
39. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:296–9.
40. Information CIH. Grey matters: a practical tool for searching health-related grey literature: CADTH.Ca 2018.
41. Covidence. Covidence systematic review software. Melbourne, Australia: Veritas Health Innovation.
42. Rohatgi A. WebPlotDigitizer. Austin, Texas USA, 2017.
43. Higgins JP, Savovic J, Page MJ. Assessing risk of bias in a randomized trial. Cochrane handbook for systematic reviews of interventions 2019:205–28.
44. Guyatt GH, Oxman AD, Vist GE, et al. Grade: an emerging consensus on rating quality of evidence and strength ofrecommendations. BMJ 2008;336:924–6.
45. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale NJ ERibaum, 1988.